JPRN-UMIN000021079已完成未知
pfront abiraterone and docetaxel administration in patients with high-risk metastatic hormone-naive prostate cancer - UFAD in mHNPC
Department of Urology, Akita University School of Medicine0 个研究点目标入组 301 人开始时间: 2016年2月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 301
研究概览
简要总结
pfront ABI provided better CRPC-free survival than upfront DOC; however, no significant differences in PFS2 or OS were observed between the two groups. Personalized management based on prognostic risk factors may benefit patients with mCSPC treated with upfront intensified therapies.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •Patients who meet the criteria below will be excluded: 1.Severe cardiovascular disease and diabetes mellitus 2.Chronic pulmonary disease 3.Allergy to taxanes 4. Active concomitant malignancy 5. Difficulty of understanding of the trial because of mental disease 6.Inappropriate patients for this study judged by the physicians
研究者
相似试验
招募中
2 期
pfront therapy in high risk metastatic prostate cancermetastatic hormone naive prostate cancerprostate cancer, hormone naive, metastaticJPRN-jRCTs021180021arita Shintaro100
尚未招募
2 期
To study whether maintenance treatment with Abiraterone after docetaxel chemotherapy leads to further improvement in metastatic hormone sensitive prostate cancer.CTRI/2020/02/023447Tata Memorial Centre
招募中
3 期
The study of compairing benefit of Abiraterone low versus full dose with Docetaxel in Prostate CancerCTRI/2023/03/050180Tata Memorial Hospital
已完成
2 期
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific AntigenProstatic NeoplasmProstate CancerNCT01314118Janssen Biotech, Inc.131
已完成
2 期
Therapeutic Strategy in Advanced Bronchioloalveolar CarcinomaAdenocarcinoma, Bronchiolo-AlveolarNCT00384826Intergroupe Francophone de Cancerologie Thoracique133